ReviewJournal of cancer research and clinical oncology2025
Advancements in the diagnosis and management of capecitabine-induced hand-foot syndrome.
Review in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Topical Delgocitinib for Capecitabine-Induced Hand-Foot Syndrome: A Therapeutic Option?Dermatology and therapy · 2026Article
- Chemotherapy-induced hand-foot syndrome among Chinese inpatients: a qualitative descriptive study in Shanghai.BMJ open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeThis narrative review aims to synthesize existing evidence on hand-foot syndrome (HFS) associated with capecitabine therapy. By examining HFS pathogenesis, clinical manifestations, severity classifications, influencing factors, and management strategies, the study seeks to provide clinically actionable insights to mitigate HFS-related quality-of-life deterioration and treatment discontinuation in patients receiving this widely used capecitabine.
methodsThis narrative review summarizes recent literature on HFS caused by capecitabine, highlighting its relationship among different populations and the prevention and treatment of HFS.
resultsThe review establishes that HFS manifests through sensory abnormalities (tingling, numbness) and dermatological changes (erythema, desquamation), though its precise pathophysiology remains incompletely defined. Incidence is modulated by demographic variables (age, sex, ethnicity), therapeutic variables (drug combinations, capecitabine dosage), and possibly genetic factors. The study highlights that co-administration of diclofenac demonstrates significant potential in reducing both HFS occurrence and symptom severity based on current evidence.
conclusionBased on critical assessment of available literature, the review concludes that the concomitant use of diclofenac with capecitabine represents an effective clinical strategy for alleviating HFS. In addition, topical urea cream, pyridoxal, lactic acid, etc. can also be used prophylactically to produce certain effects. This pharmacological approach is recommended to enhance treatment adherence and preserve patient quality of life during antineoplastic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.